Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harmony Biosciences HoldingsHRMY +1.89%95 3-Year EBITDA Growth Rate is 21.90% as of Jun. 2026, which is 50% below its 10-year median of 43.70. GuruFocus rates HRMY with a GF Score™ of 95/100 and a GF Value™ of $46.94 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,129 Biotechnology companies, Harmony Biosciences Holdings ranks better than 58.28% on this metric.
During the past 12 months, Harmony Biosciences Holdings's average EBITDA Per Share Growth Rate was 5.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 21.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 105.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Harmony Biosciences Holdings was 296.20% per year. The lowest was 21.90% per year. And the median was 43.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Harmony Biosciences Holdings 3-Year EBITDA Growth Rate Related Terms
HRMY vs SION, URGN, PVLA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Harmony Biosciences Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harmony Biosciences Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Harmony Biosciences Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 21.90% mean?
Harmony Biosciences Holdings (HRMY) has a 3-Year EBITDA Growth Rate of 21.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Harmony Biosciences Holdings and its competitors. This is 50% below median its historical median of 43.70. Over the past decade, Harmony Biosciences Holdings' 3-Year EBITDA Growth Rate has ranged from 21.90 to 296.20. According to the industry distribution chart, Harmony Biosciences Holdings ranks #471 out of 1129 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Harmony Biosciences Holdings' 3-Year EBITDA Growth Rate too high?
Harmony Biosciences Holdings' current 3-Year EBITDA Growth Rate of 21.90% is 50% below median its 10-year median of 43.70. Over the past 10 years, this metric has ranged from a low of 21.90 to a high of 296.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Harmony Biosciences Holdings' value of 21.90% is 47% above this industry median. Based on the distribution chart, Harmony Biosciences Holdings ranks #471 out of 1129 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Harmony Biosciences Holdings has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' 3-Year EBITDA Growth Rate compare to SION and URGN?
According to the Biotechnology industry distribution chart, Harmony Biosciences Holdings ranks #471 out of 1129 companies for 3-Year EBITDA Growth Rate. This puts Harmony Biosciences Holdings in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Harmony Biosciences Holdings' value of 21.90% is 47% above this benchmark. Historically, Harmony Biosciences Holdings' own 3-Year EBITDA Growth Rate has ranged from 21.90 to 296.20 over the past decade. While the company's 10-year median is 43.70 vs. the industry median of 14.90, Harmony Biosciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harmony Biosciences Holdings's current 3-Year EBITDA Growth Rate of 21.90% is 47% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Harmony Biosciences Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harmony Biosciences Holdings's current 3-Year EBITDA Growth Rate is 21.90%, which is 50% below median its own 10-year median of 43.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.94, compared to a current price of $39.61 — trading 15.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 21.90%, which is 50% below median its 10-year median of 43.70 and 47% above the Biotechnology industry median of 14.90. Harmony Biosciences Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current 3-Year EBITDA Growth Rate is 21.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?
Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued.
The current stock price of $39.61 is trading 15.6% below its estimated GF Value™ of $46.94.
GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.
Key valuation signals for HRMY:
3-Year EBITDA Growth Rate: 21.90% (50% below median its 10-year median of 43.70)
GF Value™: $46.94 vs. price of $39.61 (15.6% below fair value)
Industry Position: 47% above the Biotechnology median (#471 of 1129)
No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
95GF Score
Get the complete analysis for HRMY
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRMY has been successfully added to your 
